Kidney disease drug developer Sorbent Therapeutics raises $21M
Sorbent Therapeutics Inc. has raised a $21 million Series B round to fund Phase 2 clinical trials of a non-absorbed polymer-based drug for end-stage renal disease. The company’s renal disease drug, called CLP 1001, isn’t absorbed into the bloodstream and works by absorbing sodium and fluid from a patient’s gastrointestinal tract, said CFO and co-founder […]